TransMedics Group (NASDAQ:TMDX) Trading 8.2% Higher - What's Next?

Key Points

• TransMedics Group's stock price increased by 8.2% on Thursday, reaching a high of $116.69, though the trading volume fell significantly to approximately 429,055 shares, down 67% from the average.
• Several analysts have raised their target prices for the stock, with Oppenheimer increasing it to $150.00, reflecting a general positive outlook on TransMedics Group, which has an average rating of "Moderate Buy."
• The company reported 37.7% year-over-year revenue growth with earnings per share of $0.92, surpassing analysts' estimates and showcasing strong operational performance.

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) shot up 8.2% during mid-day trading on Thursday . The stock traded as high as $116.69 and last traded at $116.62. 429,055 shares traded hands during trading, a decline of 67% from the average session volume of 1,305,038 shares. The stock had previously closed at $107.79.

Analyst Upgrades and Downgrades

TMDX has been the subject of a number of analyst reports. Canaccord Genuity Group lifted their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, July 15th. Oppenheimer lifted their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Evercore ISI initiated coverage on shares of TransMedics Group in a research note on Tuesday. They set an "outperform" rating and a $155.00 target price for the company. Morgan Stanley lifted their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Finally, Stifel Nicolaus initiated coverage on shares of TransMedics Group in a research note on Thursday, September 4th. They set a "hold" rating and a $115.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $125.40.

TransMedics Group Price Performance

The stock has a market capitalization of $4.06 billion, a price-to-earnings ratio of 61.74 and a beta of 2.18. The business's fifty day moving average price is $115.93 and its 200-day moving average price is $106.02. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. The firm had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business's revenue was up 37.7% on a year-over-year basis. During the same period last year, the company earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. On average, research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Institutional Trading of TransMedics Group

Several hedge funds have recently added to or reduced their stakes in the stock. NBC Securities Inc. bought a new stake in shares of TransMedics Group in the first quarter valued at approximately $25,000. Opal Wealth Advisors LLC bought a new stake in shares of TransMedics Group in the second quarter valued at approximately $26,000. Smartleaf Asset Management LLC raised its position in shares of TransMedics Group by 44.3% in the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after purchasing an additional 135 shares during the period. Quarry LP raised its position in shares of TransMedics Group by 88.5% in the first quarter. Quarry LP now owns 592 shares of the company's stock valued at $40,000 after purchasing an additional 278 shares during the period. Finally, Sound Income Strategies LLC bought a new stake in shares of TransMedics Group in the second quarter valued at approximately $48,000. Institutional investors own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.